C2N Diagnostics announced in its clearance announcement that the FDA cleared PrecivityAD2 blood test on Aug. 20, 2026, for adults 40 and older with memory symptoms.
C2N Diagnostics says it estimates brain amyloid buildup tied to Alzheimer's and helps guide choices about PET imaging, spinal-fluid testing, or treatment evaluation. The clearance covers adults already being evaluated for cognitive impairment, according to C2N Diagnostics. The Alzheimer's Association notes it is not a stand-alone diagnosis.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Official resources:
- Read the official guidance from C2N — Use this primary source to verify the official guidance.
- Read the official guidance from Fixfirst — Use this primary source to verify the official guidance.
Table of Contents
- Why age 40 matters
- How the APS2 score works
- What the validation results mean
- What to do after new symptoms
Why age 40 matters
FixFirst Research reports Fujirebio Lumipulse and Roche Elecsys pTau181 were limited to ages 55 and up. PrecivityAD2 lowered that floor by 15 years to age 40. Those earlier clearances came in May 2025 and Oct.
2025. It is the first FDA-cleared test for symptomatic adults as young as 40, according to FixFirst Research. For adults 40 to 54 with new symptoms, evaluation can now include a cleared blood-test option.
How the APS2 score works
C2N Diagnostics describes PrecivityAD2 as high-resolution mass spectrometry of plasma. It measures two blood markers, Aβ42/40 ratio and percent p-tau217.
An algorithm combines both results into Amyloid Probability Score 2, or APS2. The score runs 0 to 100 and shows likelihood of brain amyloid pathology.
What the validation results mean
FixFirst Research summarizes a 1,142-person study in people with cognitive symptoms in its validation summary. Researchers compared PrecivityAD2 with amyloid PET or spinal-fluid testing.
According to FixFirst Research, the test showed 97.6% positive predictive value for ruling in amyloid pathology. It showed 93.1% negative predictive value for ruling out amyloid pathology. A high score pointed strongly toward amyloid, while a low score made amyloid unlikely.
What to do after new symptoms
The Alzheimer's Association notes in its labeling summary that the test must be used with a standard clinical workup. A professional experienced in cognitive-impairment evaluation must order and interpret it. It is not cleared for population screening.
It is not a stand-alone diagnosis. Medical News Today reported C2N's expectation that the FDA-cleared version would arrive later in 2026 while the CLIA-validated laboratory version stayed available. Newly symptomatic adults 40 and older can review this checklist with a clinician:.
- Age 40 or older
- Signs or symptoms of cognitive impairment
- Already undergoing evaluation for Alzheimer's disease
- Clinician-ordered blood test guides whether PET, spinal-fluid testing, or treatment evaluation is needed
You Might Also Like
- Medicare-Linked Dementia Survey Data Priorities in 2026: How Adults With Memory Concerns Can Avoid Overreading the Headline
- Day-One Subcutaneous Leqembi for Early Alzheimer’s in 2026: Safety and Monitoring Questions for People With Early Alzheimer’s
- Vitamin Supplements in the 2026 WHO Dementia Guideline: What the Evidence Supports and Does Not Promise for Adults in Midlife





